Curve Therapeutics in US$1.7bn deal with MSD
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1281 entries already.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital has launched a new life sciences fund with initial capital commitments of 50m and a target size of 150m.
European investment firm LSP has closed its European life sciences fund LSP at 1 bn. Additionally, a 10bn fund of funds was greenlighted at the EU Council in Paris.
AiCuris will pay up to 100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
AGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.
EU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide 10bn for late-state tech companies.
Ribbon Biolabs has cashed in 18m in Series A financing led by Hadean Ventures
German mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital.
Pfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age.
Norways immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater.